Selected FXR Agonist PBC Studies: Conference Coverage of AASLD

12/13/23 • 17 min

During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.

In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including:

A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid
Lessons learned from a long-term outcomes study of people with PBC
Results from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid

Presenter:

Kris V. Kowdley MD, FAASLD, FACP, FACG
Professor, Elson S. Floyd College of Medicine
Washington State University
Director, Liver Institute Northwest
Seattle, Washington

Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI

In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including:

A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid
Lessons learned from a long-term outcomes study of people with PBC
Results from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid

Presenter:

Kris V. Kowdley MD, FAASLD, FACP, FACG
Professor, Elson S. Floyd College of Medicine
Washington State University
Director, Liver Institute Northwest
Seattle, Washington

Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI

Previous Episode

PrEP Talks: Strategies for Advanced Practice Providers to Increase Uptake

In this episode, Dr Tavell Kindall and Jona Tanguay discuss actionable strategies for advanced practice providers to increase the frequency at which PrEP is offered and initiated in primary care settings. Topics covered include:

Available training resources on how to offer PrEP in primary care
Affordable, accessible PrEP options, including patient assistance programs
Using electronic health records to identify candidates for PrEP
Opportunities to offer PrEP during appointments regarding birth control, STIs, or any other sexual health concerns
How to offer 3-site STI testing at your facility
Wrapping PrEP into primary care
Incorporating navigators or care coordinators to reduce logistical barriers and reach underserved populations
Rapid testing, mobile testing, and Tele-PrEP as ways to facilitate PrEP initiation and simplify routine PrEP visits
Healthcare professionals’ personal biases as a potential barrier to PrEP
Using ICD-10 codes for HIV PrEP as a way to further destigmatize PrEP and simplify billing

Faculty:

Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP
Director, HIV Prevention and Treatment
St. Thomas Community Health Center
New Orleans, Louisiana

Jona Tanguay, MMSc, PA-C, AAHIVS
Medical Program Lead - Substance Use Disorders at Whitman-Walker Health
Associate Medical Director - Transgender Health at Amida Care
President-Elect at GLMA: Health Professionals Advancing LGBTQ+ Equality
Clinical Instructor at Yale School of Medicine
Founder at ChemsexHarmReduction.org
Washington, DC

Content is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Link to full program:
https://bit.ly/3PZGYdR

Next Episode

Providing Options for PrEP Reengagement: Strategies to Support PrEP Persistence and Reengagement

In this episode, Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discusses data and recommendations for providing HIV prevention options as a strategy to support PrEP persistence and engagement, including:

Postexposure prophylaxis (PEP) recommendations and the data for PEP-in-Pocket
Offering PrEP to everyone who receives PEP
Currently recommended PrEP options and the safety and adverse event considerations with each option
Monitoring recommendations for the different PrEP options
The importance of proactively addressing PrEP safety concerns that could lead to PrEP discontinuation

Faculty

Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES
Assistant Professor
Pharmacotherapeutics and Clinical Research
University of South Florida Taneja College of Medicine
Tampa, Florida

Follow along with the slides:
bit.ly/48cULUN

Link to full program:
bit.ly/3ZlICsL